Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome

Pediatric Heart Network Investigators, New England Research Institutes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To assess health-related quality of life (HRQOL) in a large multicenter cohort of children and young adults with Marfan syndrome participating in the Pediatric Heart Network Marfan Trial. Study design: The Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales were administered to 321 subjects with Marfan syndrome (5-25 years). PedsQL scores were compared with healthy population norms. The impact of treatment arm (atenolol vs losartan), severity of clinical features, and number of patient-reported symptoms on HRQOL was assessed by general linear models. Results: Mean PedsQL scores in children (5-18 years) with Marfan syndrome were lower than healthy population norms for physical (P ≤.003) and psychosocial (P <.001) domains; mean psychosocial scores for adults (19-25 years) were greater than healthy norms (P <.001). HRQOL across multiple domains correlated inversely with frequency of patient-reported symptoms (r = 0.30-0.38, P <.0001). Those <18 years of age with neurodevelopmental disorders (mainly learning disability, attention-deficit/hyperactivity disorder) had lower mean PedsQL scores (5.5-7.4 lower, P <.04). A multivariable model found age, sex, patient-reported symptoms, and neurodevelopmental disorder to be independent predictors of HRQOL. There were no differences in HRQOL scores by treatment arm, aortic root z score, number of skeletal features, or presence of ectopia lentis. Conclusions: Children and adolescents with Marfan syndrome were at high risk for impaired HRQOL. Patient-reported symptoms and neurodevelopmental disorder, but not treatment arm or severity of Marfan syndrome-related physical findings, were associated with lower HRQOL.

Original languageEnglish (US)
Pages (from-to)250-255.e1
JournalJournal of Pediatrics
Volume204
DOIs
StatePublished - Jan 2019

Fingerprint

Marfan Syndrome
Young Adult
Quality of Life
Ectopia Lentis
Pediatrics
Atenolol
Losartan
Learning Disorders
Attention Deficit Disorder with Hyperactivity
Population
Linear Models
Therapeutics
Equipment and Supplies

Keywords

  • neurodevelopmental disorders
  • patient-reported symptoms

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pediatric Heart Network Investigators, & New England Research Institutes (2019). Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. Journal of Pediatrics, 204, 250-255.e1. https://doi.org/10.1016/j.jpeds.2018.08.061

Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. / Pediatric Heart Network Investigators; New England Research Institutes.

In: Journal of Pediatrics, Vol. 204, 01.2019, p. 250-255.e1.

Research output: Contribution to journalArticle

Pediatric Heart Network Investigators & New England Research Institutes 2019, 'Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome', Journal of Pediatrics, vol. 204, pp. 250-255.e1. https://doi.org/10.1016/j.jpeds.2018.08.061
Pediatric Heart Network Investigators, New England Research Institutes. Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. Journal of Pediatrics. 2019 Jan;204:250-255.e1. https://doi.org/10.1016/j.jpeds.2018.08.061
Pediatric Heart Network Investigators ; New England Research Institutes. / Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. In: Journal of Pediatrics. 2019 ; Vol. 204. pp. 250-255.e1.
@article{68af02a44cd04e5b822295c3e44dbd24,
title = "Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome",
abstract = "Objective: To assess health-related quality of life (HRQOL) in a large multicenter cohort of children and young adults with Marfan syndrome participating in the Pediatric Heart Network Marfan Trial. Study design: The Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales were administered to 321 subjects with Marfan syndrome (5-25 years). PedsQL scores were compared with healthy population norms. The impact of treatment arm (atenolol vs losartan), severity of clinical features, and number of patient-reported symptoms on HRQOL was assessed by general linear models. Results: Mean PedsQL scores in children (5-18 years) with Marfan syndrome were lower than healthy population norms for physical (P ≤.003) and psychosocial (P <.001) domains; mean psychosocial scores for adults (19-25 years) were greater than healthy norms (P <.001). HRQOL across multiple domains correlated inversely with frequency of patient-reported symptoms (r = 0.30-0.38, P <.0001). Those <18 years of age with neurodevelopmental disorders (mainly learning disability, attention-deficit/hyperactivity disorder) had lower mean PedsQL scores (5.5-7.4 lower, P <.04). A multivariable model found age, sex, patient-reported symptoms, and neurodevelopmental disorder to be independent predictors of HRQOL. There were no differences in HRQOL scores by treatment arm, aortic root z score, number of skeletal features, or presence of ectopia lentis. Conclusions: Children and adolescents with Marfan syndrome were at high risk for impaired HRQOL. Patient-reported symptoms and neurodevelopmental disorder, but not treatment arm or severity of Marfan syndrome-related physical findings, were associated with lower HRQOL.",
keywords = "neurodevelopmental disorders, patient-reported symptoms",
author = "{Pediatric Heart Network Investigators} and {New England Research Institutes} and Handisides, {Jill C.} and Danielle Hollenbeck-Pringle and Karen Uzark and Trachtenberg, {Felicia L.} and Pemberton, {Victoria L.} and Atz, {Teresa W.} and Bradley, {Timothy J.} and Elizabeth Cappella and {De Nobele}, Sylvia and Groh, {Georgeann Keh Teng} and Hamstra, {Michelle S.} and Rosalind Korsin and Levine, {Jami C.} and Bergen Lindauer and Aimee Liou and Neal, {Meghan K.Mac} and Markham, {Larry W.} and Tonia Morrison and Mussatto, {Kathleen A.} and Olson, {Aaron K.} and Pierpont, {Mary Ella M.} and Pyeritz, {Reed E.} and Radojewski, {Elizabeth A.} and Roman, {Mary J.} and Mingfen Xu and Lacro, {Ronald V.} and Gail Pearson and Mario Stylianou and Lynn Mahony and Lynn Sleeper and Sharon Tennstedt and Steven Colan and Gloria Klein and Lin Guey and Lisa Wruck and Thomas Travison and Shan Chen and Eric Gerstenberger and Tanya Olesker and Teitel, {David F.} and Jane Newburger and Martha King and Carolyn Dunbar-Masterson and Andrea Posa and Quincy Nang and Cara Hass and Daphne Hsu and Wyman Lai and William Hellenbrand and Beth Printz",
year = "2019",
month = "1",
doi = "10.1016/j.jpeds.2018.08.061",
language = "English (US)",
volume = "204",
pages = "250--255.e1",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome

AU - Pediatric Heart Network Investigators

AU - New England Research Institutes

AU - Handisides, Jill C.

AU - Hollenbeck-Pringle, Danielle

AU - Uzark, Karen

AU - Trachtenberg, Felicia L.

AU - Pemberton, Victoria L.

AU - Atz, Teresa W.

AU - Bradley, Timothy J.

AU - Cappella, Elizabeth

AU - De Nobele, Sylvia

AU - Groh, Georgeann Keh Teng

AU - Hamstra, Michelle S.

AU - Korsin, Rosalind

AU - Levine, Jami C.

AU - Lindauer, Bergen

AU - Liou, Aimee

AU - Neal, Meghan K.Mac

AU - Markham, Larry W.

AU - Morrison, Tonia

AU - Mussatto, Kathleen A.

AU - Olson, Aaron K.

AU - Pierpont, Mary Ella M.

AU - Pyeritz, Reed E.

AU - Radojewski, Elizabeth A.

AU - Roman, Mary J.

AU - Xu, Mingfen

AU - Lacro, Ronald V.

AU - Pearson, Gail

AU - Stylianou, Mario

AU - Mahony, Lynn

AU - Sleeper, Lynn

AU - Tennstedt, Sharon

AU - Colan, Steven

AU - Klein, Gloria

AU - Guey, Lin

AU - Wruck, Lisa

AU - Travison, Thomas

AU - Chen, Shan

AU - Gerstenberger, Eric

AU - Olesker, Tanya

AU - Teitel, David F.

AU - Newburger, Jane

AU - King, Martha

AU - Dunbar-Masterson, Carolyn

AU - Posa, Andrea

AU - Nang, Quincy

AU - Hass, Cara

AU - Hsu, Daphne

AU - Lai, Wyman

AU - Hellenbrand, William

AU - Printz, Beth

PY - 2019/1

Y1 - 2019/1

N2 - Objective: To assess health-related quality of life (HRQOL) in a large multicenter cohort of children and young adults with Marfan syndrome participating in the Pediatric Heart Network Marfan Trial. Study design: The Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales were administered to 321 subjects with Marfan syndrome (5-25 years). PedsQL scores were compared with healthy population norms. The impact of treatment arm (atenolol vs losartan), severity of clinical features, and number of patient-reported symptoms on HRQOL was assessed by general linear models. Results: Mean PedsQL scores in children (5-18 years) with Marfan syndrome were lower than healthy population norms for physical (P ≤.003) and psychosocial (P <.001) domains; mean psychosocial scores for adults (19-25 years) were greater than healthy norms (P <.001). HRQOL across multiple domains correlated inversely with frequency of patient-reported symptoms (r = 0.30-0.38, P <.0001). Those <18 years of age with neurodevelopmental disorders (mainly learning disability, attention-deficit/hyperactivity disorder) had lower mean PedsQL scores (5.5-7.4 lower, P <.04). A multivariable model found age, sex, patient-reported symptoms, and neurodevelopmental disorder to be independent predictors of HRQOL. There were no differences in HRQOL scores by treatment arm, aortic root z score, number of skeletal features, or presence of ectopia lentis. Conclusions: Children and adolescents with Marfan syndrome were at high risk for impaired HRQOL. Patient-reported symptoms and neurodevelopmental disorder, but not treatment arm or severity of Marfan syndrome-related physical findings, were associated with lower HRQOL.

AB - Objective: To assess health-related quality of life (HRQOL) in a large multicenter cohort of children and young adults with Marfan syndrome participating in the Pediatric Heart Network Marfan Trial. Study design: The Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales were administered to 321 subjects with Marfan syndrome (5-25 years). PedsQL scores were compared with healthy population norms. The impact of treatment arm (atenolol vs losartan), severity of clinical features, and number of patient-reported symptoms on HRQOL was assessed by general linear models. Results: Mean PedsQL scores in children (5-18 years) with Marfan syndrome were lower than healthy population norms for physical (P ≤.003) and psychosocial (P <.001) domains; mean psychosocial scores for adults (19-25 years) were greater than healthy norms (P <.001). HRQOL across multiple domains correlated inversely with frequency of patient-reported symptoms (r = 0.30-0.38, P <.0001). Those <18 years of age with neurodevelopmental disorders (mainly learning disability, attention-deficit/hyperactivity disorder) had lower mean PedsQL scores (5.5-7.4 lower, P <.04). A multivariable model found age, sex, patient-reported symptoms, and neurodevelopmental disorder to be independent predictors of HRQOL. There were no differences in HRQOL scores by treatment arm, aortic root z score, number of skeletal features, or presence of ectopia lentis. Conclusions: Children and adolescents with Marfan syndrome were at high risk for impaired HRQOL. Patient-reported symptoms and neurodevelopmental disorder, but not treatment arm or severity of Marfan syndrome-related physical findings, were associated with lower HRQOL.

KW - neurodevelopmental disorders

KW - patient-reported symptoms

UR - http://www.scopus.com/inward/record.url?scp=85053937143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053937143&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2018.08.061

DO - 10.1016/j.jpeds.2018.08.061

M3 - Article

C2 - 30270167

AN - SCOPUS:85053937143

VL - 204

SP - 250-255.e1

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

ER -